Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

Catalent (NYSE:CTLT) was cut to neutral from outperform at Baird as the analyst can't predict the valuation of the contract drug manufacturing if its deal to be sold to the Novo Nordisk Foundation isn ...

Michelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC's 'Closing Bell' to discuss the criticism Novo ...

The maker of diabetes and weight-loss drugs Ozempic and Wegovy was in the hot seat Tuesday as Vermont Sen. Bernie Sanders ...

Sen. Bernie Sanders grilled Novo Nordisk's CEO Lars Jorgensen over the cost of the company's weight loss and diabetes ...

Sen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

Senators grilled Novo Nordisk CEO Lars Jørgensen Tuesday at a hearing over the costs of Ozempic, Wegovy and similar weight loss drugs. The drugs have risen in popularity for diabetic patients and ...

On Tuesday, the CDC’s National Center for Health Statistics released its latest report analyzing data on the state of obesity ...

Novo Nordisk is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The Danish drugmaker's CEO Lars Jorgensen challenged Medicare's ...

Bloomberg News Now is a comprehensive audio report on today's top stories. Listen for the latest news, whenever you want it, covering global business stories around the world.

The Senate HELP Committee held a hearing to address the high cost of semaglutide drugs, finding that many patients cannot ...